Company type | Public |
---|---|
SIX: RO (voting) SIX: ROG (non-voting) | |
ISIN | CH0012032048 |
Industry | Pharmaceuticals |
Predecessor | Hoffmann, Traub & Co. (1894) |
Founded | 1 October 1896 |
Founder | Fritz Hoffmann-La Roche |
Headquarters | Basel, Switzerland |
Area served | Worldwide |
Key people |
|
Products | Pharmaceuticals and diagnostics (List of products) |
Revenue | CHF 60.44 billion (2023) |
CHF 15.39 billion (2023) | |
CHF 12.36 billion (2023) | |
Total assets | CHF 90.47 billion (2023) |
Total equity | CHF 33.26 billion (2023) |
Number of employees | 103,605 (2023) |
Subsidiaries | |
Website | roche |
Footnotes / references [4] |
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue[5] and the leading provider of cancer treatments globally.[6][7] In 2023, the company’s seat in Forbes Global 2000 was 76.[8]
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares until 2021. Roche is one of the few companies increasing their dividend every year, for 2020 as the 34th consecutive year.
F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[9]47°33′31″N 7°36′22″E / 47.558624°N 7.606018°E